TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer

NCT03193853 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Cancer

Interventions

DRUG: Tak-228 & Tak-117
DRUG: Cisplatin & Nab Paclitaxel

Sponsor

Joyce O'Shaughnessy

Collaborators

[object Object]